Heat-sensitive moxibustion combined with tropisetron hydrochloride for chemotherapy-induced nausea and vomiting: a randomized controlled trial
Objective
To compare the effectiveness of heat-sensitive moxibustion combined with tropisetron hydrochloride versus tropisetron hydrochloride alone in treating chemotherapy-induced nausea and vomiting (CINV).
Methods
Sixty CINV patients were randomly divided into two groups. The control group received tropisetron hydrochloride, while the observation group received heat-sensitive moxibustion in addition to tropisetron hydrochloride. The treatment lasted for 7 days starting from the day of chemotherapy. The occurrence and severity of nausea and vomiting were recorded, and the complete remission rate was evaluated. The KPS score, quality of life scale score, and incidence of myelosuppression were compared between the two groups.
Results
The observation group showed lower incidence and severity of nausea and vomiting, higher complete remission rates, improved KPS score, and better quality of life compared to the control group. The incidence of myelosuppression was also lower in the observation group.
Conclusion
Heat-sensitive moxibustion combined with tropisetron hydrochloride effectively reduces nausea and vomiting after chemotherapy, improves quality of life, and relieves myelosuppression in patients with malignant tumors.
Practical Solutions and Value
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates clinical standards and research, making knowledge easily accessible for clinicians. Streamlining operations is crucial in today’s healthcare environment, and our mobile apps support scheduling, monitoring treatments, and telemedicine, enhancing workflows and improving patient outcomes while reducing paper routines. Learn more about how we can help at aidevmd.com.
